UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Anti-TIGIT to overcome resistance to immune checkpoint inhibitors in lung cancer: limits and potentials

Annals of oncology, 2022-02, Vol.33 (2), p.119-122

2022

Volltextzugriff (PDF)

Testing for COVID-19 in lung cancer patients

Annals of oncology, 2020-07, Vol.31 (7), p.832-834

2020

Volltextzugriff (PDF)

Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges

Journal for immunotherapy of cancer, 2019-08, Vol.7 (1), p.205-13, Article 205

2019

Volltextzugriff (PDF)

The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes

European journal of cancer (1990), 2018-09, Vol.101, p.191-200

2018

Volltextzugriff (PDF)

First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology

ESMO open, 2022-02, Vol.7 (1), p.100355, Article 100355

2022

Volltextzugriff (PDF)

Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT)

ESMO open, 2023-04, Vol.8 (2), p.101192-101192, Article 101192

2023

Volltextzugriff (PDF)

Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC): Platelet-to-lymphocyte ratio (PLR) predicts the risk of development and relapse

Annals of oncology, 2019-04, Vol.30, p.ii58-ii59

2019

Volltextzugriff (PDF)

Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers

Clinical lung cancer, 2023-01, Vol.24 (1), p.e19-e26

2023

Volltextzugriff (PDF)

Potentialities of liquid biopsy in advanced non-small cell lung cancer (aNSCLC): Early evaluation of sentinel mutations in plasma and outcome of patients treated with immunotherapy

Annals of oncology, 2019-04, Vol.30, p.ii9-ii9

2019

Volltextzugriff (PDF)

Liquid biopsy as tool to monitor and predict clinical benefit from chemotherapy (CT) and immunotherapy (IT) in advanced non-small cell lung cancer (aNSCLC): A prospective study

Annals of oncology, 2018-10, Vol.29, p.viii649-viii649

2018

Volltextzugriff (PDF)

Clinical features of never smoker patients with lung squamous cell carcinoma: a retrospective multicenter study

Annals of oncology, 2017-10, Vol.28, p.vi60-vi60

2017

Volltextzugriff (PDF)

Surgery in multimodal management in non-metastatic small cell lung cancer: a retrospective monocentric series

Annals of oncology, 2017-10, Vol.28, p.vi61-vi61

2017

Volltextzugriff (PDF)

Data Analysis for Direct Numerical Simulations of Turbulent Combustion: From Equation-Based Analysis to Machine Learning

1st Edition 2020, 2020

Volltextzugriff (PDF)

42P Comparative real-world analysis of pembrolizumab plus chemo vs platinum-doublet alone in metastatic non-squamous NSCLC with PD-L1 low

Annals of oncology, 2022-04, Vol.33, p.S51

2022

Volltextzugriff (PDF)

P1.23-06 Liquid Biopsy Predicts Differential Benefit from First Line Pembrolizumab in Advanced Non-small Cell Lung Cancer

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S257

2023

Volltextzugriff (PDF)

1124P Pralsetinib in RET fusion-positive non-small cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP)

Annals of oncology, 2022-09, Vol.33, p.S1065

2022

Volltextzugriff (PDF)

129P Association of clinico-pathological markers with longitudinal liquid biopsy (LB) results predicts outcome in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs)

Annals of oncology, 2022-09, Vol.33, p.S596

2022

Volltextzugriff (PDF)

1048P Molecular predictors of immunotherapy efficacy in lung squamous-cell carcinoma (LSCC): Results from the randomized prospective SQUINT trial

Annals of oncology, 2022-09, Vol.33, p.S1033

2022

Volltextzugriff (PDF)

1939P Potential role of longitudinal plasma next generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) experiencing hyperprogression (HPD) and early death (ED) during treatment with immune checkpoint inhibitors (ICIs)

Annals of oncology, 2020-09, Vol.31, p.S1096-S1096

2020

Volltextzugriff (PDF)

158PImmune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC): Platelet-to-lymphocyte ratio (PLR) predicts the risk of development and relapse

Annals of oncology, 2019-04, Vol.30 (Supplement_2)

2019

Volltextzugriff (PDF)

EP08.01-030 Nivolumab+Ipilimumab Vs Platinum-Based CT+Nivolumab In Advanced Lung Squamous-Cell Carcinoma: The Randomized SQUINT Trial

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S351

2022

Volltextzugriff (PDF)

P2.05-02 MAPK1/MAPK3 Mutations Enhance Immunotherapy Efficacy in Lung Squamous Cell Carcinoma (LSCC): Results of the SQUINT Trial

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S307

2023

Volltextzugriff (PDF)

1967PTriple MET/SRC/PIM inhibition in MET addicted tumors

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Triple MET/SRC/PIM inhibition in MET addicted tumors

Annals of oncology, 2019-10, Vol.30, p.v791

2019

Volltextzugriff (PDF)

1 – 25 von 1.475

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.209)
Mit Volltextzugriff
(1.207)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(694)
Life Sciences & Biomedicine
(502)
Humans
(366)
Female
(222)
Male
(209)
Middle Aged
(170)
Physical Sciences
(154)
Technology
(129)
Gastroenterology & Hepatology
(128)
Aged
(123)
Adult
(115)
Gastroenterology And Hepatology
(108)
Biological And Medical Sciences
(104)
Oncology
(92)
Medical Sciences
(88)
Engineering
(81)
Animals
(62)
Physics
(62)
Radiology, Nuclear Medicine & Medical Imaging
(58)
Energy & Fuels
(52)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Anti-TIGIT to overcome resistance to immune checkpoint inhibitors in lung cancer: limits and potentials

Testing for COVID-19 in lung cancer patients

Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges

The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes

First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology

Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT)

Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC): Platelet-to-lymphocyte ratio (PLR) predicts the risk of development and relapse

Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers

Potentialities of liquid biopsy in advanced non-small cell lung cancer (aNSCLC): Early evaluation of sentinel mutations in plasma and outcome of patients treated with immunotherapy

Liquid biopsy as tool to monitor and predict clinical benefit from chemotherapy (CT) and immunotherapy (IT) in advanced non-small cell lung cancer (aNSCLC): A prospective study

Clinical features of never smoker patients with lung squamous cell carcinoma: a retrospective multicenter study

Surgery in multimodal management in non-metastatic small cell lung cancer: a retrospective monocentric series

Data Analysis for Direct Numerical Simulations of Turbulent Combustion: From Equation-Based Analysis to Machine Learning

42P Comparative real-world analysis of pembrolizumab plus chemo vs platinum-doublet alone in metastatic non-squamous NSCLC with PD-L1 low

EUS-guided choledochoduodenostomy for malignant distal biliary obstruction after failed ERCP: a retrospective nationwide analysis

P1.23-06 Liquid Biopsy Predicts Differential Benefit from First Line Pembrolizumab in Advanced Non-small Cell Lung Cancer

1124P Pralsetinib in RET fusion-positive non-small cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP)

129P Association of clinico-pathological markers with longitudinal liquid biopsy (LB) results predicts outcome in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs)

1048P Molecular predictors of immunotherapy efficacy in lung squamous-cell carcinoma (LSCC): Results from the randomized prospective SQUINT trial

1939P Potential role of longitudinal plasma next generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) experiencing hyperprogression (HPD) and early death (ED) during treatment with immune checkpoint inhibitors (ICIs)

158PImmune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC): Platelet-to-lymphocyte ratio (PLR) predicts the risk of development and relapse

EP08.01-030 Nivolumab+Ipilimumab Vs Platinum-Based CT+Nivolumab In Advanced Lung Squamous-Cell Carcinoma: The Randomized SQUINT Trial

P2.05-02 MAPK1/MAPK3 Mutations Enhance Immunotherapy Efficacy in Lung Squamous Cell Carcinoma (LSCC): Results of the SQUINT Trial

1967PTriple MET/SRC/PIM inhibition in MET addicted tumors

Triple MET/SRC/PIM inhibition in MET addicted tumors

Suchergebnisse filtern